David I Quinn

David I Quinn

UNVERIFIED PROFILE

Are you David I Quinn?   Register this Author

Register author
David I Quinn

David I Quinn

Publications by authors named "David I Quinn"

Are you David I Quinn?   Register this Author

100Publications

3064Reads

44Profile Views

Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with F-FDG PET/CT.

J Nucl Med 2019 Nov 29;60(11):1524-1530. Epub 2019 Mar 29.

Division of Cancer Medicine, Department of Medicine, Kenneth J. Norris, Jr., Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836859PMC
November 2019

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

Cancer 2019 Nov 9;125(21):3853-3863. Epub 2019 Aug 9.

Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32290DOI Listing
November 2019

Radium-223 mechanism of action: implications for use in treatment combinations.

Nat Rev Urol 2019 Nov 11. Epub 2019 Nov 11.

Johns Hopkins University, School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0251-xDOI Listing
November 2019

Editorial Comment.

J Urol 2019 Oct 29:10109701JU00006123720204748. Epub 2019 Oct 29.

Section of Genitourinary Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JU.0000612372.02047.48DOI Listing
October 2019

Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.

Cancer Treat Res Commun 2019 10;18:100114. Epub 2018 Nov 10.

USC Norris Comprehensive Cancer Center, Division of Medical Oncology. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2018.100114DOI Listing
August 2019

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Clin Genitourin Cancer 2019 Aug 19;17(4):241-247.e1. Epub 2019 Mar 19.

Lawrence J. Ellison Institute for Transformative Medicine of USC and Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.010DOI Listing
August 2019

Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.

Int J Radiat Oncol Biol Phys 2019 05 31;104(1):50-60. Epub 2018 Dec 31.

Department of Preventative Medicine, University of Southern California Keck School of Medicine, Los Angeles, California.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016183422
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2018.12.047DOI Listing
May 2019

Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?

Clin Genitourin Cancer 2018 08 6;16(4):e719-e727. Epub 2018 Feb 6.

Department of Preventative Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.01.018DOI Listing
August 2018

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

J Clin Oncol 2018 06 28;36(16):1579-1587. Epub 2018 Mar 28.

David J. Vaughn, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Yves Fradet, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; Jae Lyun Lee, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea; Lawrence Fong, University of California, San Francisco, San Francisco; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Miguel A. Climent, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Daniel P. Petrylak, Smilow Cancer Hospital, Yale University, New Haven, CT; Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan; Cora N. Sternberg, San Camillo and Forlanini Hospitals, Rome, Italy; Winald Gerritsen, Radboud University Medical Center, Nijmegen; Ronald de Wit, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; Howard Gurney, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia; Stephane Culine, Hôpital Saint-Louis, Paris, France; Yabing Mai, Haojie Li, and Rodolfo F. Perini, Merk & Co., Inc., Kenilworth, NJ; and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.9562
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.9562DOI Listing
June 2018

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

J Clin Oncol 2018 05 6;36(15):1498-1504. Epub 2018 Apr 6.

Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Catherine M. Tangen, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Ian M. Thompson Jr, University of Texas Health Science Center, San Antonio; Gregory P. Swanson, Baylor Scott and White Health, Temple, TX; David P. Wood, Beaumont Physician Partners and Clinical Faculty, Royal Oak; Wael Sakr, Wayne State University School of Medicine, Detroit, MI; Nancy A. Dawson, Lombardi Comprehensive Cancer Center, Washington, DC; Naomi B. Haas, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Thomas W. Flaig, E. David Crawford, and L. Michael Glode, University of Colorado Cancer Center, Denver, CO; Tanya B. Dorff and David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; and Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959197PMC
May 2018

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Clin Genitourin Cancer 2017 12 8;15(6):742-749. Epub 2017 Jun 8.

Division of Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.06.002DOI Listing
December 2017

Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients.

Clin Genitourin Cancer 2017 Sep 6. Epub 2017 Sep 6.

Keck School of Medicine, Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.08.016DOI Listing
September 2017

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers.

Urol Oncol 2017 07 9;35(7):459.e15-459.e24. Epub 2017 Mar 9.

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.01.021DOI Listing
July 2017

Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.

Clin Adv Hematol Oncol 2017 Jul;15(7):543-551

Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.

View Article

Download full-text PDF

Source
July 2017

Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).

Clin Genitourin Cancer 2017 Jul 14. Epub 2017 Jul 14.

Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA; Department of Medicine/Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.003DOI Listing
July 2017

Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.

Clin Adv Hematol Oncol 2017 Jun;15(6):466-477

Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.

View Article

Download full-text PDF

Source
June 2017

Comparative effectiveness of screening strategies for colorectal cancer.

Cancer 2017 05 24;123(9):1516-1527. Epub 2017 Jan 24.

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30518DOI Listing
May 2017

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

N Engl J Med 2017 03 17;376(11):1015-1026. Epub 2017 Feb 17.

From Dana-Farber Cancer Institute, Boston (J.B., T.K.C.); Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona (J.B.), and Fundación Instituto Valenciano de Oncología, Valencia (M.A.C.) - both in Spain; Erasmus MC Cancer Institute, Rotterdam (R.W.), and Radboud University Medical Center, Nijmegen (W.G.) - both in the Netherlands; Abramson Cancer Center, University of Pennsylvania, Philadelphia (D.J.V.); Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (Y.F.); Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); the University of California, San Francisco, San Francisco (L.F.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Smilow Cancer Hospital, Yale University, New Haven, CT (D.P.P.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Westmead Hospital and Macquarie University, Sydney (H.G.); the University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles (D.I.Q.); Hôpital Saint-Louis, Paris (S.C.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Merck, Kenilworth, NJ (Y.M., C.H.P., R.F.P.); and Memorial Sloan Kettering Cancer Center, New York (D.F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635424PMC
March 2017

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

Clin Genitourin Cancer 2016 10 6;14(5):450-456.e1. Epub 2016 Feb 6.

USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.01.013DOI Listing
October 2016

What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer.

J Nucl Med 2016 Oct;57(Suppl 3):6S-12S

Division of Medical Oncology, Department of Medicine, Keck School of Medicine at USC, USC Norris Comprehensive Cancer Center and Hospital, Los Angeles, California

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.170142DOI Listing
October 2016

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.

Onco Targets Ther 2016 23;9:5825-5837. Epub 2016 Sep 23.

Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045229PMC
http://dx.doi.org/10.2147/OTT.S97397DOI Listing
September 2016

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

J Clin Oncol 2016 07 16;34(21):2478-83. Epub 2016 May 16.

Darren R. Feldman, Kristina Lim, Sujata Patil, Kaitlin M. Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Memorial Sloan Kettering Cancer Center; Darren R. Feldman, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Weill Medical College of Cornell University, New York, NY; and James Hu, Tanya B. Dorff, Siamak Daneshmand, Charlene Ketchens, and David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320896PMC
July 2016

Safety and feasibility of fasting in combination with platinum-based chemotherapy.

BMC Cancer 2016 06 10;16:360. Epub 2016 Jun 10.

USC Keck School of Medicine, Norris Comprehensive Cancer Center, 1441 Eastlake Ave. #3440, Los Angeles, CA, 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2370-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4901417PMC
June 2016

AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.

Prostate 2016 May 15;76(6):597-608. Epub 2016 Jan 15.

Division of Medical Oncology, Department of Medicine, University of Southern California Keck School of Medicine and Translational and Clinical Science Program, USC Norris Comprehensive Cancer Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23151DOI Listing
May 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0218DOI Listing
May 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

N Engl J Med 2015 Nov 25;373(19):1872-4. Epub 2015 Sep 25.

From the University of Southern California Norris Comprehensive Cancer Center, Los Angeles (D.I.Q.), and the University of California Davis Comprehensive Cancer Center, Sacramento (P.N.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1511252DOI Listing
November 2015

Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

J Urol 2015 Aug 21;194(2):378-85. Epub 2015 Feb 21.

University of Southern California Institute of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/early/2013/04/23/jnci
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S002253471500394
Publisher Site
http://dx.doi.org/10.1016/j.juro.2015.02.084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834920PMC
August 2015

Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story.

Urol Oncol 2015 Aug 18;33(8):341-2. Epub 2015 Jun 18.

Division of Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.05.023DOI Listing
August 2015

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.

Cancer Biother Radiopharm 2015 Jun 6;30(5):195-9. Epub 2015 Mar 6.

1 Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California , Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2014.1802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492702PMC
June 2015

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.

Urol Oncol 2015 May 7;33(5):245-60. Epub 2015 Jan 7.

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2014.10.009DOI Listing
May 2015

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol 2015 May 6;33(14):1601-8. Epub 2015 Apr 6.

Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417730PMC
May 2015

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.

Target Oncol 2015 Mar 5;10(1):45-53. Epub 2014 Mar 5.

Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, Mail Code R35, 9500 Euclid Avenue, Cleveland, 44195, OH, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-014-0307-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363524PMC
March 2015

Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases.

Radiology 2015 Feb;274(2):624-5

Departments of Radiology (H.J.), Preventive Medicine (S.G.G.), and Medicine (D.I.Q.), Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.14141593DOI Listing
February 2015

Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.

Cancer Chemother Pharmacol 2014 Dec 6;74(6):1227-34. Epub 2014 Nov 6.

Division of Medical Oncology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2600-zDOI Listing
December 2014

Chromoplexy and hypoxic microenvironment drives prostate cancer.

Lancet Oncol 2014 Dec 13;15(13):1419-1421. Epub 2014 Nov 13.

Department of Radiation Oncology, Institute of Urology and Division of Oncology, Department of Medicine, Keck School of University of Southern California and USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)71114-3DOI Listing
December 2014

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.

BMC Cancer 2014 Dec 16;14:966. Epub 2014 Dec 16.

Department of Urology, USC/Norris Comprehensive Cancer Center, USC Institute of Urology, 1441 Eastlake Abe, Suite 7416, Los Angeles, CA 90089, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301463PMC
December 2014

Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.

Cell Stem Cell 2014 Jun;14(6):810-23

Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, CA 90089, USA; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, Keck School of Medicine, University of Southern California, 1425 San Pablo Street, Los Angeles, CA 90033, USA; IFOM, FIRC Institute of Molecular Oncology, Via Adamello, 16, 20139 Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2014.04.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102383PMC
June 2014

Salvage chemotherapy for refractory germ cell tumors.

Oncology (Williston Park) 2014 Jun;28(6):498-500

View Article

Download full-text PDF

Source
June 2014

Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.

Clin Genitourin Cancer 2014 Apr 14;12(2):e55-8. Epub 2013 Nov 14.

Department of Medicine, USC Keck School of Medicine, Los Angeles, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.11.006DOI Listing
April 2014

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

J Natl Cancer Inst 2014 Apr 24;106(4):dju013. Epub 2014 Feb 24.

Affiliations of authors: University of California Davis Comprehensive Cancer Center, Sacramento, CA (PNL, PCM); Southwest Oncology Group Statistical Center, Seattle, WA (BE, CT); University of Southern California Norris Cancer Center, Los Angeles, CA (DIQ, AG); USDA Western Human Nutrition Center at University of California Davis, Davis, CA (EG, MVL); City of Hope, Duarte, CA (PT); University of Michigan, Ann Arbor, MI (MH), US Oncology, Las Vegas, NV (NJV); Cancer Treatment and Research Center, University of Texas, San Antonio, TX (IT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982883PMC
April 2014

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

J Clin Oncol 2014 Apr 10;32(11):1136-42. Epub 2014 Mar 10.

Amir Goldkorn, David I. Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles; Przemyslaw Twardowski, City of Hope, Duarte; Philip C. Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA; Benjamin Ely and Catherine M. Tangen, Southwest Oncology Group Statistical Center; Celestia S. Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA; Louis M. Fink, Nevada Cancer Institute; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV; Peter J. Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Michael A. Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD; J. Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH; Ram H. Datar and Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL; Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, OR; Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Ian Murchie Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.7417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970171PMC
April 2014

Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.

Expert Rev Anticancer Ther 2014 Jan;14(1):51-61

Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://search.proquest.com/openview/a3792b8afdb6152d2ddbeabd
Web Search
http://www.tandfonline.com/doi/full/10.1586/14737140.2014.84
Publisher Site
http://dx.doi.org/10.1586/14737140.2014.848065DOI Listing
January 2014

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases.

Urology 2014 Jan 12;83(1):159-65. Epub 2013 Nov 12.

Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2013.08.074DOI Listing
January 2014

Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients.

Urol Oncol 2014 Jan 13;32(1):52.e1-9. Epub 2013 Nov 13.

Institute of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2013.08.007DOI Listing
January 2014

Novel tyrosine kinase inhibitors for renal cell carcinoma.

Expert Rev Clin Pharmacol 2014 Jan 2;7(1):67-73. Epub 2013 Dec 2.

Department of Medicine, USC Keck School of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave. #3440, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2014.862496DOI Listing
January 2014

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.

Clin Genitourin Cancer 2013 Dec 4;11(4):416-22. Epub 2013 Oct 4.

University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.07.011DOI Listing
December 2013

Targeted α-particle therapy of bone metastases in prostate cancer.

Clin Nucl Med 2013 Dec;38(12):966-71

From the Divisions of *Nuclear Medicine, Department of Radiology, and †Cancer Medicine, Department of Medicine, Kenneth J. Norris Jr. Comprehensive CancerCenter, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000000290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874447PMC
December 2013

Differentiating mTOR inhibitors in renal cell carcinoma.

Cancer Treat Rev 2013 Nov 21;39(7):709-19. Epub 2013 Feb 21.

Department of Medical Oncology & Experimental Therapeutics, Division of Genitourinary Malignancies, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957946PMC
November 2013

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

J Nucl Med 2013 Aug 19;54(8):1195-201. Epub 2013 Jun 19.

Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, California 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.112.114116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783857PMC
August 2013

Tivozanib in the treatment of renal cell carcinoma.

Biologics 2013 11;7:139-48. Epub 2013 Jun 11.

Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S32958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684142PMC
June 2013

Small cell bladder cancer: biology and management.

Semin Oncol 2012 Oct;39(5):615-8

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2012.08.009DOI Listing
October 2012

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Clin Nucl Med 2012 Jul;37(7):637-43

Division of Nuclear Medicine, Department of Radiology, Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0b013e318252d829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375600PMC
July 2012

Immune response to sipuleucel-T in prostate cancer.

Cancers (Basel) 2012 Apr 18;4(2):420-41. Epub 2012 Apr 18.

Keck School of Medicine at USC, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3440, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers4020420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712699PMC
April 2012

Blood cells and their use in active immunotherapy of prostate cancer.

Hum Vaccin Immunother 2012 Apr 28;8(4):528-33. Epub 2012 Feb 28.

University of Southern California, Medicine, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/hv.19188DOI Listing
April 2012

Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.

BJU Int 2012 Mar 4;109(6):846-54. Epub 2011 Aug 4.

Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2011.10455.xDOI Listing
March 2012

Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.

Mol Cancer Ther 2012 Mar 17;11(3):526-37. Epub 2012 Feb 17.

Division of Genitourinary Oncology, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-11
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-11-0806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297694PMC
March 2012

The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.

Clin Adv Hematol Oncol 2011 Dec;9(12 Suppl 28):1-14; quiz 15-6

Divisions of Medical Oncology and Urology, Duke Cancer Institute and the Duke Prostate Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
December 2011

FDG PET/CT demonstration of pancreatic metastasis from prostate cancer.

Clin Nucl Med 2011 Oct;36(10):961-2

Department of Radiology, PET Imaging Science Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0b013e3182291d1aDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167095PMC
October 2011

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Maturitas 2011 Aug 31;69(4):296-303. Epub 2011 May 31.

Division of Cancer Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.maturitas.2011.04.012DOI Listing
August 2011